drugset / Trial / NCT04515732
Danish Population-based Assessment of Psoriasis and Psoriatic Arthritis (DANPAPP)
Phase 4
Unknown
115 enrolled
Professor Mikkel Østergaard
Celgene Corporation · collabThe Danish Psoriasis Association · collabThe Danish Rheumatism Association · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
3-part study of patients with psoriasis, including 1) a population based questionnaire 2) cross-sectional clinical study with focus on musculoskeletal ultrasound and patient reported outcomes 3) 12 months follow-up study of patients with certain ultrasonic signs of psoriatic arthritis. Patients with pain: Interventional with 6 months treatment with apremilast, followed by 6 months observation. Patients without pain: 12 months observation.
Timeline
- Start
- 2018-12-14
- Primary completion
- 2021-04
- Completion
- 2021-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apremilast | Small molecule | 30 mg | Oral |